



1rw DAC
PATENT
12013/56301

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Application No. : 09/542,935
Inventor : Maria PALASIS
Filed : April 4, 2000
For : **INSERTABLE OR IMPLANTABLE MEDICAL
DEVICES SUITABLE FOR GENE THERAPY
REGIMENS**
Examiner : Brian A. Whiteman
Art Unit : 1635

Mail Stop Petitions
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Date: February 12, 2008

Signature:


Joseph A. Coppola (Reg. No. 38,413)

**REQUEST FOR RECONSIDERATION OF DECISION ON
PETITION TO REVIVE
ABANDONED APPLICATION UNDER 37 C.F.R. §1.138(b)**

SIR:

On September 25, 2007, Applicants petitioned to withdraw holding of abandonment based on failure to submit a Petition for Extension of Time in the above-identified application.

Applicant filed a continuation application, now U.S. Patent Application Serial No. 11/901,235, on September 14, 2007, which is based on and claims priority to Patent Application Serial No. 09/542,925 identified above. Inadvertently, Applicant did not file a Petition for Extension of Time in the above-identified parent case. Accordingly, Applicant filed a Petition to Revive and Petition for Extension of Time in the above-referenced parent case.

However, and again inadvertently, Applicant failed to submit a copy of said continuation application papers, which constituted the required response in the case, along with the Petition.

Consequently, in the absence of the required response, Applicant's Petition was dismissed.

Therefore, Applicant hereby requests reconsideration of the Petition filed on September 25, 2007, and submits copies of the following papers:

- (1) The September 25, 2007 Petition to Revive and Petition for Extension of Time;
and
- (2) The Continuation Application Transmittal (including the official Filing Receipt) and accompanying papers as filed in response to the final Office Action in U.S. Patent Application Serial No. 09/542,935 and in which an Appeal Brief was due on September 16, 2007.

Applicant notes that MPEP 711.03(c) (Petitions Relating to Abandonment), at section II. A. 2(c)(c), states:

Abandonment for Failure To File an Appeal Brief

In those situations where abandonment occurred because of the failure to file an appeal brief, the reply required pursuant to 37 CFR 1.137(a)(1) or 1.137(b)(1) must be either:

- (A) an appeal brief in compliance with 37 CFR 41.37 (c) and appeal brief fee;
- (B) the filing of an RCE accompanied by a submission and the requisite fee in compliance with 37 CFR 1.114 for utility or plant applications filed on or after June 8, 1995 (see paragraph (d) below); or
- (C) the filing of a continuing application under 37 CFR 1.53(b) (or a CPA under 37 CFR 1.53(d) if the application is a design application).

By filing a continuation application, Applicants complied with item (C) above, and thus satisfied the requirements for a reply.

The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition was unintentional.

Applicant has now complied with the requirement to provide the required reply with the Petition, the required fee, and the required statement that the entire delay in filing the required reply was unintentional. Accordingly, Applicant hereby respectfully requests reconsideration of the Petition to Revive which was originally filed on September 25, 2007.


No fees are believed to be due for this Request for Reconsideration of Decision on Petition to Withdraw Holding of Abandonment, however, the Commissioner is hereby authorized to charge

any fee, if necessary. The Commissioner is also authorized to credit any overpayment in connection with these papers to Deposit Account No. 11-0600.

Respectfully submitted,

Date: February 12, 2008

By:




Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON LLP
One Broadway
New York, NY 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)

CUSTOMER NO. 26646



UNITED STATES PATENT AND TRADEMARK OFFICE



Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

KENYON & KENYON LLP
ONE BROADWAY
NEW YORK NY 10004

COPY MAILED

JAN 25 2008

OFFICE OF PETITIONS

ON PETITION

In re Application of :
Palasis, Maria :
Application No. 09/542,935 :
Filed: April 4, 2000 :
Attorney Docket No. 02844/56301 :

This is a decision on the petition under 37 C.F.R. § 1.137(b), filed September 25, 2007, to revive the above-identified application.

The petition is **DISMISSED**.

Any request for reconsideration must be submitted within TWO (2) MONTHS from the mail date of this decision. No further petition fee is required for the request. Extensions of time under 37 CFR 1.136(a) are permitted. The reconsideration request should include a cover letter entitled "Renewed Petition under 37 CFR 1.137(b)." This is **not** a final agency action within the meaning of 5 U.S.C. § 704.

A grantable petition under 37 CFR 1.137(b) must be accompanied by:

- (1) the required reply,¹
- (2) the petition fee,
- (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137(b) was unintentional, and
- (4) a terminal disclaimer and fee if the application was filed on or before June 8, 1995 or if the application is a design application.

Where there is a question as to whether either the abandonment or the delay in filing a petition² under 37 CFR 1.137 was unintentional, the Commissioner may require additional information.

The instant petition lacks item(s) (1). A Notice of Appeal was filed on February 16, 2007, which set a 2-month period for filing the appeal brief accompanied by the fee required by law. As required by 37 CFR 1.137(b), the required reply is necessary for revival, which in this case, is the appeal brief.

Accordingly, submission of the appeal brief is necessary for revival.

¹ In a nonprovisional application abandoned for failure to prosecute, the required reply may be met by the filing of a continuing application. In an application or patent, abandoned or lapsed for failure to pay the issue fee or any portion thereof, the required reply must be the payment of the issue fee or any outstanding balance thereof.

² See MPEP 711.03(c)(III)(C) and (D).

Further correspondence with respect to this matter should be addressed as follows:


By mail: Mail Stop PETITIONS
Commissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450

By hand: Customer Window located at:

U.S. Patent and Trademark Office
Customer Service Window Randolph Building
401 Dulany Street
Alexandria, VA 22314

By fax: (571) 273-8300
ATTN: Office of Petitions

Any questions concerning this matter may be directed to the undersigned at (571) 272-3206.


Liana Walsh
Petitions Examiner
Office of Petitions

RECEIVED
CENTRAL FAX CENTER
SEP 25 2007



Fax Transmission

From: **Josephine Hardy
For Joseph A. Coppola, Esq.**

Date: **Sept. 25, 2007**

Direct Dial: **212.908.6437**

Fax: **212.425.5288**

Client/Matter: **12013/56301**
Serial No.: **09/542,935**

Total number of pages: **05**
(including cover)

Please deliver to:

Name	Company	Fax	Phone
Mail Stop Petitions	U.S. Patent and Trademark Office	<u>571-273 8300</u>	

PETITION TO REVIVE and PETITION FOR EXTENSION OF TIME

SIR:

Applicants in patent application Serial No. 09/542,935 submit herewith a Petition to Revive (2 pages) and a Petition for Extension of Time (2 copies of 1 page each for accounting purposes), for a total of 5 pages including this fax cover sheet.

If you have any questions, please contact Applicants' attorney at 212.425.7200.

Very truly yours,

Josephine Hardy
Legal Assistant to Joseph A. Coppola

Cc: **Joseph A. Coppola, Esq.**

X Original will not follow Original will follow by Regular Mail Overnight Delivery Hand Delivery
The information contained in this facsimile transmission, including any attachments, is subject to the attorney-client privilege, the attorney work product privilege or is confidential information intended only for the use of the named recipient. If the reader of this Notice is not the intended recipient or the employee or agent responsible for delivering this transmission to the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone, so that we may arrange for its return or destruction at our cost. Thank you.

New York Washington, DC Silicon Valley www.kenyon.com

SEP-25-2007

18:21

FEB 19 2008

KENYON & KENYON

RECEIVED
CENTRAL FAX CENTER

P. 04

SEP 25 2007

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. § 1.136(a) and FEE TRANSMITTAL for Petition to Revive Patent Application Unintentionally Abandoned		Docket Number: 12013/56301	
Application Number 09/542,935	Filing Date April 4, 2000	Examiner B. A. Whiteman	Art Unit 1635
Invention Title INSERTABLE OR IMPLANTABLE MEDICAL DEVICES SUITABLE FOR GENE THERAPY REGIMENS		Inventor(s) Maria PALASIS	

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing

I hereby certify that this Petition for Extension of Time is being transmitted
by facsimile on the date shown below to the United States Patent and
Trademark Office at (571) 273-8300 on September 25, 2007.
Joseph A. Coppola (Reg. No 38,413)

SIR:

Applicants hereby respectfully request a **five-month extension of time** in which to file a
response from the Notice of Appeal filed on February 16, 2007 in the above-identified application.
The initial response date was April 16, 2007; the five-month extended period ends on **September 16,
2007**.

The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.136(a), **five
month extension** fee of \$2,160.00 to the Kenyon & Kenyon LLP Deposit Account Number 11-0600.


Further, Applicants hereby authorize the Commissioner to charge payment of the 37 C.F.R.
1.17(m) petition fee of \$1,500.00 to the Kenyon & Kenyon LLP Deposit Account Number 11-0600
(see Petition attached).

The Commissioner is also authorized to charge any additional fees or credit any overpayment
in connection with this paper to Deposit Account No. 11-0600. A copy of this form is enclosed for
charging purposes.

Respectfully submitted,

Dated : September 25, 2007

By:


Joseph A. Coppola (Reg. No. 38,413)KENYON & KENYON LLP
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

Customer Number 26646

SEP-25-2007



KENYON & KENYON

RECEIVED
CENTRAL FAX CENTER P. 05

SEP 25 2007

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. § 1.136(a) and FEE TRANSMITTAL for Petition to Revive Patent Application Unintentionally Abandoned		Docket Number: 12013/56301	
Application Number 09/542,935	Filing Date April 4, 2000	Examiner B. A. Whiteman	Art Unit 1635
Invention Title INSERTABLE OR IMPLANTABLE MEDICAL DEVICES SUITABLE FOR GENE THERAPY REGIMENS		Inventor(s) Maria PALASIS	

Address to:
 Mail Stop AF
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Certificate of Mailing

I hereby certify that this Petition for Extension of Time is being transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (571) 273-8300 on September 25, 2007.

Joseph A. Coppola (Reg. No 38,413)

SIR:

Applicants hereby respectfully request a five-month extension of time in which to file a response from the Notice of Appeal filed on February 16, 2007 in the above-identified application. The initial response date was April 16, 2007; the five-month extended period ends on September 16, 2007.

The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.136(a), five month extension fee of \$2,160.00 to the Kenyon & Kenyon LLP Deposit Account Number 11-0600.

Further, Applicants hereby authorize the Commissioner to charge payment of the 37 C.F.R. 1.17(m) petition fee of \$1,500.00 to the Kenyon & Kenyon LLP Deposit Account Number 11-0600 (see Petition attached).

The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600. A copy of this form is enclosed for charging purposes.

Respectfully submitted 09/25/2007 VBU11 00000039 110600 09542935

Dated : September 25, 2007

By:

Joseph A. Coppola (Reg. No. 38,413)

02 FC:1255 2160.00 DA

Customer Number 26646

KENYON & KENYON LLP
 One Broadway
 New York, N.Y. 10004
 (212) 425-7200 (telephone)
 (212) 425-5288 (facsimile)

NY01 1311338 v1

RECEIVED
CENTRAL FAX CENTER
SEP 25 2007



PTO/SB/64 (04-07)

Approved for use through 09/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT
ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)**

Docket Number (Optional)
12013/56301

First named inventor: Maria PALASIS

Application No.: 09/542,935

Art Unit: 1635

Filed: April 4, 2000

Examiner: B.A. Whiteman

Title: INSERTABLE OR IMPLANTABLE MEDICAL DEVICES SUITABLE FOR GENE THERAPY REGIMES

**Attention: Office of Petitions
Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
FAX (571) 273-8300**

NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (571) 272-3282.

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus an extensions of time actually obtained.

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee;
- (2) Reply and/or issue fee;
- (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995; and for all design applications; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee

☐ Small entity-fee \$ _____ (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.

☒ Other than small entity – fee \$ 1,500.00 (37 CFR 1.17(m))

2. Reply and/or fee

A. The reply and/or fee to the above-noted Office action in the form of PETITION FOR EXTENSION OF TIME (identify type of reply):

☐ has been filed previously on _____
☒ is enclosed herewith.

B. The issue fee and publication fee (if applicable) of \$ _____
☐ has been paid previously on _____ 09/26/2007 VBU11 00000039 110600
☐ is enclosed herewith.

09/26/2007 VBUI11 00000039 110600

01 FC:1453

1500.00 DA

89542935

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

SEP 25 2007

PTO/SB/64 (04-07)

Approved for use through 09/30/2007. OMB 0851-0031.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee

☒ Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.

☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ _____ for a small entity or \$ _____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE: The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D)).]

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

Joseph A. Coppola
Signature

SEPTEMBER 25, 2007

Date

JOSEPH A. COPPOLA

Typed or printed name

38,413

Registration Number, if applicable

KENYON & KENYON LLP

Address

121.425.7200

Telephone Number

ONE BROADWAY, NEW YORK, NY 10004-1007

Address

Enclosures: ☒ Fee Payment

☐ Reply

☐ Terminal Disclaimer Form

☐ Additional sheets containing statements establishing unintentional delay

☒ Other: PETITION FOR EXTENSION OF TIME

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

☐ Deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

☒ Transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (571) 273-8300.

SEPTEMBER 25, 2007

Date

Joseph A. Coppola
Signature

JOSEPH A. COPPOLA

Typed or printed name of person signing certificate

[Page 2 of 2]



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
11/901,235	09/14/2007	1635	1260	12013/56302	22	2

CONFIRMATION NO. 4525

UPDATED FILING RECEIPT



OC000000026638098

26646
KENYON & KENYON LLP
ONE BROADWAY
NEW YORK, NY 10004

Date Mailed: 11/07/2007

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Applicant(s)

Maria Palasis, Wellesley, MA;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 09/542,935 04/04/2000

Foreign Applications

If Required, Foreign Filing License Granted: 10/02/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 11/901,235**

Projected Publication Date: 02/14/2008

Non-Publication Request: No

Early Publication Request: No

Title

Insertable or implantable medical devices suitable for gene therapy regimens

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as


set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLMS	IND CLMS
11/901,235	09/14/2007	1635	0.00	12013/56302	51	2

CONFIRMATION NO. 4525

26646
 KENYON & KENYON LLP
 ONE BROADWAY
 NEW YORK, NY 10004

FILING RECEIPT



OC000000026115844

Date Mailed: 10/02/2007

Receipt is acknowledged of this nonprovisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Maria Palasis, Wellesley, MA;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 09/542,935 04/04/2000

Foreign Applications

If Required, Foreign Filing License Granted: 10/02/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US11/901,235**

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Insertable or implantable medical devices suitable for gene therapy regimens

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof

unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



EM0794413731112 12013156302 JAC 9/11/07

The stamp of the Patent Office hereon, may be taken as

acknowledging the receipt, on the date stamped, of

Continuation
PATENT APPLICATION of

Title *Insertable Or Implantable Medical Devices*
Suit For Gene Therapy Regimes

U.S. PTO



Specifications 37 pgs

Assignment 11901235

No. of claims _____

Recording fee \$ 091407

No. of drawings _____

Authorization to charge Dep. Acct. _____

Declaration copy

Priority Document _____

Filing fee \$ _____

Preliminary Amendment _____

Non-Publications request _____

Small Entity _____

No fee is being paid at this time
IPS a PTO Form 1449



P31766US2

Coppel
Weller

EM07944331US 1203156302 JAC 9111607

The stamp of the Patent Office hereon, may be taken as

acknowledging the receipt, on the date stamped, of

^{Permanence}
PATENT APPLICATION of

Title Inventable Or Implantable Medical Devices
And For Gene Therapy Regimens

Specifications 37pgs Assignment _____
No. of claims _____ Recording fee \$ _____
No. of drawings _____ Authorization to charge Dep. Acct. _____
Declaration copy Priority Document _____
Filing fee \$ _____ Preliminary Amendment _____

Non-Publications request _____ Small Entity _____

No fee is being paid at this time
IPs are PTO for m 14449

EM07944331US

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

PATENT APPLICATION TRANSMITTAL LETTER
UNDER 37 C.F.R. 1.53(b)

ATTORNEY DOCKET NO.:
12013/56302

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith for filing is a continuation patent application of

Inventor(s): **Maria PALASIS**

For : **INSERTABLE OR IMPLANTABLE MEDICAL DEVICES SUITABLE FOR
GENE THERAPY REGIMES**

Priority Claimed:

This application is a continuation of and claims priority under 35 U.S.C. § 120 to United States Patent Application Serial No. 09/542,935, filed on April 4, 2000; which is incorporated herein by reference in its entirety.


Enclosed are:

1. Thirty-seven (37) pages of application (including twenty-nine (29) pages of specification, seven (7) pages of claims, and one (1) page of abstract.
2. Declaration (copy from parent application Serial No. 09/542,935).
3. Incorporation by Reference. The entire disclosures of all prior applications are considered as being part of the disclosure of the accompanying application and are hereby incorporated in their entirety by reference herein.
4. Other enclosures:
Information Disclosure Statement and PTO-1449 Form.
Return Receipt Postcard.
5. The filing fees are not being paid at this time.
6. A copy of this sheet is enclosed.

Dated: SEPT. 14, 2007

Respectfully submitted,

By:



Joseph A. Coppola (Reg. No. 38,413)
Kenyon & Kenyon LLP
One Broadway
New York, NY 10004
Customer Nos. 26646 and 23838

**INSERTABLE OR IMPLANTABLE MEDICAL DEVICES SUITABLE
FOR GENE THERAPY REGIMENS.**

Field of the Invention

The present invention relates to a method and medical device for controlled delivery and long term expression of one or more products and therapeutic agents within the body of a patient. In particular, this invention relates to gene or cell therapies wherein the genetic material is coated on a surface of an insertable or implantable medical device and is delivered to a target location in the patient's body.

I. Background of the Invention

Gene therapy provides an attractive approach for combating many intractable cardiovascular diseases. Prior art gene therapy regimens suffer from several limitations rendering application of this therapy unsuccessful in a clinical setting. Short term expression of therapeutic gene products, low levels of gene expression, and lack of site-specificity are among several factors that are responsible for the failure of this system of therapy *in vivo*. The lack of adequate integration into the host genome, or the rejection of the transgene or carrier vector by the immune response, are among several factors that account for the short duration and low level expression of gene products.

Advances in interventional radiology and innovative designs in balloon angioplasty

and stents have raised the therapeutic potential of gene and cell therapy regimens. Long term delivery of drugs has been achieved through sustained and localized delivery of drugs *in vivo*. One potential drawback to conventional localized drug administration is the uncontrolled manner by which the drug or drug solution is released from the delivery device. It is often
5 necessary to control and/or lengthen the time period over which the drug is released. For example, it might be advantageous to lengthen the release time from hours to days or even weeks. Exceptionally long release times, as long as several months, are often desired, for example, where the drug is released from an implanted device such as a stent.

The therapeutic use of conventional drug delivery devices is further limited by
10 problems associated with the increased trauma to the vessel wall, rapid washout of drug, use of therapeutic agents having a single mechanism of action, and the like. For a more comprehensive review of this subject see, for example: "Effect of controlled adventitial heparin delivery on smooth muscle proliferation following endothelial injury", Edelman E., *et al.*, Proc. Natl. Acad. Sci. U.S.A., 87:3773, 1990; "Localized release of perivascular
15 heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation", Okada T., *et al.*, Neurosurgery, 25:892, 1989; "Iontophoretic transmyocardial drug delivery: A novel approach to antiarrhythmic drug therapy", Avitall B., *et al.*, CIRC., 85:1582, 1992; "Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplasty," Wilinsky R., *et al.*, Amer.
20 Heart J., 122: 1136, 1991; and "Local anticoagulation without systemic effect using a polymer heparin delivery system", Okada T., *et al.*, Stroke, 19:1470, 1988.

One way to achieve site-specificity and long term expression of a therapeutic gene

product *in vivo* is the incorporation of genetic material, in the form of a naked or plasmid DNA, into a device coating. Transformation efficiency of naked or plasmid DNA, however, is very low relative to DNA delivered by a lipid carrier or by viral vectors. Viral vectors present a very efficient means of introducing foreign genes into cells. Unfortunately, viral
5 vectors are usually very labile and thus not able to withstand the coating process without losing activity. Thus, the incorporation of viral particles into a device coating is likely not to be feasible in its present form.

Several reports in scientific literature indicate that recombinant viral vectors facilitate efficient transfer of foreign genes into somatic tissues, including vascular endothelial and
10 smooth muscle cells. Early therapy-directed strategies relied on gene transfer by placement of a device containing transformed cells within the body of a patient. The concept of direct gene transfer to the target cell population, obviating the need for cell culture, has prompted the development of catheter based gene delivery systems. Although several prototype systems have demonstrated *in vivo* delivery of viral vectors to a vascular wall, resulting in
15 expression of foreign genes, currently available systems are limited by the quantity and infectivity of virus delivered, traumatic injury to the vessel wall during delivery, and interruption of blood flow during delivery.

Adenoassociated virus (AAV) is a viral particle with unique characteristics. It is solvent and heat stable so that it may withstand the processing conditions required to
20 incorporate the virus into a device coating. Furthermore, it can be stored at room temperature for several months without losing activity. The use of vectors derived from adenoassociated virus vectors for transferring genes *in vitro* and *in vivo* has been described (see, in particular,

U.S. Pat. Nos. 4,797,368; 5,139,941; and 5,851,521 each of which is incorporated herein by reference). These patents describe various adenoassociated virus derived constructs in which the replicase (rep) or cap genes are deleted and replaced by a gene of interest.

5 A drawback to adenoassociated virus delivery of genes is that the onset of protein expression is delayed by approximately two weeks post introduction into the cell. Treatment of proliferative diseases such as restenosis will likely require immediate protein expression in order to effect the proliferative response which generally peaks about three days post device implantation and usually subsides by two weeks.

10 This invention, as disclosed and described herein, overcomes the above-mentioned limitations of prior art gene delivery and drug delivery systems. The device of this invention facilitates delivery of a polynucleotide sequence of interest in a controlled and stable manner *in vivo*. The mechanical problems associated with the prior art insertable or implantable medical devices have been overcome by the invention described herein via the use of a polymer coating which is capable of providing adequate tensile strength, permitting control
15 of porosity and hydration capacity of the device. A new gene therapy regimen is disclosed that overcomes prior art problems regarding stability during coating process, site-specificity, and stability of expression of a polynucleotide sequence *in vivo*.

20 These characteristics, and several others as disclosed herein, render the medical device of this invention desirable for a variety of therapeutic methods, including gene and cell therapies.

II. Summary of the Invention

In one aspect of the invention, there is provided a medical device having a biocompatible structure carrying a genetic material. The biocompatible structure comprises a biocompatible polymeric coating that coats at least a portion of the structure and carries a genetic material. The genetic material comprises: (a) a first therapeutic agent comprising a vector containing a first polynucleotide that establishes a gene expression sufficient to produce a therapeutically sufficient amount of one or more products encoded by said first polynucleotide; and (b) a second therapeutic agent comprising at least one of (i) a second polynucleotide carried by a carrier; (ii) a protein; (iii) a non-genetic therapeutic agent, or (iv) cells.

The genetically coated medical device of the invention preferably comprises a stent, catheter or combination thereof. In a more preferred embodiment of this invention, the medical device or structure of the invention comprises a stent composed of a biocompatible material, including biostable or biodegradable materials. More preferably, the stent is a metallic stent. The stent is in any shape and made of any biocompatible material suitable for keeping all or part of a tubular or spiral apparatus in an opened, expanded, coiled or tubular form during storage and/or following implantation. Suitable biocompatible materials for a stent include, but are not limited to, stainless steel, nickel, silver, platinum, gold, titanium, iridium, tungsten, Ni-Ti Alloys (*i.e.*, Nitinol), inconel, poly-L-lactic acid (PLLA) / poly ϵ -caprolactone (PCL) blends, and the like.

According to another aspect of the invention, there is provided a method of inhibiting

or treating restenosis in a subject, preferably a mammal, by administering to the subject, at a predetermined site in the body, the medical device of the invention. The site of administration is preferably a site of mechanical injury to an arterial wall produced by treatment of an atherosclerotic lesion by angioplasty.

5 In yet another aspect of the invention, there is provided a method of controlled delivery of a genetic material to a subject. The method comprises: (A) applying a polymer coating to at least a portion of a medical device; (B) applying a genetic material to said polymer coating to obtain a genetically coated medical device, said genetic material comprising: (a) a first therapeutic agent comprising a vector containing a first polynucleotide that establishes
10 a gene expression sufficient to produce a therapeutically sufficient amount of one or more products encoded by said first polynucleotide; and (b) a second therapeutic agent comprising at least one of (i) a second polynucleotide carried by a carrier; (ii) a protein; (iii) a non-genetic therapeutic agent; or (iv) cells; and (C) inserting or implanting said genetically coated medical device at a predetermined site in said mammal. Steps (A) and (B) are not limited
15 to orderly steps and the method encompasses application of B prior to or concurrent with A.

III. Detailed Description Of The Invention

As used herein, the following terms are defined as follows:

20 "*Naked polynucleotide*", as used herein includes any nucleic acid molecule, not incorporated into a viral, plasmid, or other non-plasmid polynucleotide carrier.

"*Genetic material*", as used herein, includes any biologically active material used

in the cell therapy or gene therapy of this invention, whether, *in vivo*, *ex vivo* or *in vitro* cultures, including; bacterial, viral, prokaryotic or eukaryotic cell cultures in a transformed or non-transformed states; native or foreign polynucleotides, recombinant or natural polynucleotides, including reporter genes, marker genes, regulatory sequences, antisense molecules, and the like. Additionally, the genetic material may include non-genetic agents
5 in combination with aforementioned compounds and compositions.

"**Product**", as used herein, includes any protein, peptide, polypeptide, polynucleotide, in sense or antisense orientation, including DNA, RNA, DNA/RNA hybrids. The terms protein, peptide, and polypeptide are used interchangeably herein.

10 "Therapeutic agent", as used herein, includes any compound, composition or small molecule that induces a beneficial biological or a medical reaction *in vitro*, *ex vivo*, or *in vivo*. The therapeutic agents are, for example, any protein, peptide, polypeptide, polynucleotides, small molecules, antibiotics, non-genetic agents, therapeutic polymers, cells or a combination thereof.

15 "Medical device", as used herein, includes any implantable or insertable medical device, whether in part or in whole.

"**Stent**", as used herein, includes any tubular or helical device used to maintain or support a bodily orifice or cavity, including grafts.

"**Balloon catheter**", as used herein, includes a catheter having a balloon or multiple
20 balloons that can be inflated or deflated without removal of the catheter after insertion into the body.

"**Therapeutically sufficient amount**", as described herein means, an effective amount

of an agent or product that is determined based on the nature and the chemical composition of the particular agent or product used.

This invention describes a medical device and a method to deliver a genetic material within the vasculature or ducts of a patient. The method and device of the invention, as
5 disclosed herein, provide control over the delivery, target location, time of exposure, duration and amount of a one or more products and therapeutic agents within the body of a patient. Local expression of genes is particularly desirable in therapies involving the use of a chemotherapeutic agent, specifically when therapy is directed to a particular organ or site and requires non-systemic exposure of that site within the body. The gene delivery system,
10 according to this invention, in combination with the use of devices such as stents or intravenous catheters, provides an effective device and system of gene delivery *both in vivo* and *ex vivo*.

The medical device of this invention is a device adapted for introduction into the body, for example, into the esophagus, trachea, colon, intestines, biliary tract, urinary tract,
15 vascular system, ureters, urethra, bronchi, pancreatic duct system, gut, nasolacrimal duct, sinus cavities, eye, fallopian tubes, and the like.

Specifically, as disclosed herein, the medical device, according to this invention, is any insertable or implantable medical device. Examples of the medical device of the invention, include without limitation, catheters, stents, needle injection catheter, blood clot
20 filters, vascular grafts, stent grafts, biliary stents, colonic stents, bronchial/pulmonary stents, esophageal stents, urethral stents, aneurysm filling coils and other coiled coil devices, trans myocardial revascularization ("TMR") devices, percutaneous myocardial revascularization

("PMR"), hypodermic needles, soft tissue clips, holding devices, and the like.

The medical device of the invention is delivered to and /or implanted at target locations by known techniques. Delivery is optionally performed with a sheath that covers the coated medical device to help inhibit the release of the genetic material prior to reaching
5 a target location.

While the structure included in the medical device may be configured in a variety of ways, the structure is preferably configured as a stent composed of a biocompatible material, including biostable or biodegradable materials. More preferably, the stent is a metallic stent. The stent is in any shape and made of any biocompatible material suitable for keeping all or
10 part of a tubular or coiled coil apparatus in an opened, expanded, coiled or tubular form during storage and/or following implantation. Suitable biocompatible materials for a stent include, but are not limited to, stainless steel, nickel, silver, platinum, gold, titanium, iridium, tungsten, Ni-Ti Alloys (*i.e.*, Nitinol), inconel, poly-L-lactic acid (PLLA) / poly ϵ -caprolactone (PCL) blends, or the like.

15 In a preferred embodiment of this invention, there is provided on the outer surface of a medical device, such as stent, a biodegradable, resorbable polymer. The stent, according to the invention disclosed herein, provides adequate tensile strength to function as a scaffolding device, permits control of porosity and hydration capacity, and, when desired, degrades into products that are nontoxic to the genetic material impregnated thereon or to the
20 cells of the vascular wall of the patient.

Included within the scope of this invention are stents that comprise a microporous tube or coil spring fabricated, for example, from aliphatic polyester blends using a fluorination-

precipitation or manual casting/winding techniques.

Another preferred medical device for use with the present invention is a coated stent that is used in conjunction with a balloon catheter. According to this embodiment of the invention, a stent attached to a balloon catheter is introduced into an artery. Inflation of the
5 balloon expands the stent and presses it slightly into the wall of the treated artery. When the balloon is deflated, the stent is left behind to bolster the arterial wall. More preferably, the stent is a balloon-expandable stent or a self-expanding stent, *i.e.*, of the type formed with superelastic materials such as Nitinol, as described in U.S. Patent No. 5,954,706, incorporated herein by reference in its entirety.

10 The invention also encompasses a catheter for delivering genetic material at a desired location within the body or within the wall of body lumen. The catheter has preferably an expandable portion mounted on a catheter shaft, the expandable portion preferably being expandable to a controlled pressure, *i.e.*, to fill the cross-section of a body lumen and press against the wall of the body lumen.

15 The device, or at least one portion of a surface of the device that comes into contact with a target site, is coated with a polymeric coating. Any suitable surface of the medical device may be coated with a polymeric coating. The surfaces to be coated may comprise, for example, wells, holes, grooves, slots, flat surfaces, upper or inner surfaces, and the like contained within or on the medical device. It is not necessary that an entire surface be
20 coated, rather, merely a portion of a surface may be coated. For example, if an expandable catheter is used, at least a portion of the exterior surface of the expandable portion is coated with a polymeric coating.

In another preferred embodiment of this invention, there is provided a polymer coating that protects and covers a surface of the medical device and prevents release of the genetic material from the coating during transvascular or transductal delivery until it is delivered to the target location within the body. The polymer coating preferably regulates the release kinetics of the genetic material from the medical device.

As polymeric coating, any medically acceptable natural or synthetic polymer is used. According to one embodiment of this invention, the polymer comprises, for example, water soluble, thermally degradable, or biodegradable polymers. Examples of the polymer of this invention include, but are not limited to, polycaprolactone, polyorthoesters, polylactic acids, poly-L-lactic acid /poly ϵ -caprolactone blends, polyglycolic acids, carbowax, gelatin, chitosan, polyvinyl alcohol, polyethylene oxide, polyethylene glycol, albumin, pluronic gel F-127, collagen, alginates, cellulosic compounds, polyvinyl pyrrolidone, or a combination thereof.

Also encompassed within the scope of the invention are biostable polymers with porosity sufficient to allow release of therapeutics. Genetic material, including transformed cells do not need to be released but may stay trapped in a biostable matrix release protein.

The thickness of the polymeric coating is preferably from about 1 to about 1000 μm , more preferably from about 10 to about 100 μm , and most preferably from about 5 to about 50 μm , per total layers. Layers of polymer coating, form about 1 to about 40 layers, each layer having a thickness of from about 1 to about 10 μm / layer of coating, are applied to the appropriate surface(s) of the medical device.

When the coated surface(s) of the medical device comes into contact with the patient's

blood, or other tissues and organs within the body, the genetic material is substantially released therefrom. Depending on the choice of the polymeric coating, the site of release, or the particular gene or cell therapy strategy intended, the release of the genetic material is either immediate or follows a controlled lag time of about 1 to several minutes (for example, 1, 5, 10, 20, 30, 60, or 90 minutes) to allow the medical device to reach the target site.

The genetic material, according to one embodiment of this invention, includes one or more polynucleotides, carried by a vector in combination with a carrier. The vector and the carrier are each part of the first and the second therapeutic agent, respectively. The vector, carrier, or both, are used to transform, transfect, or transduce eukaryotic or prokaryotic cells, which cells are then applied onto or impregnated into the same or a different layer of coating. The terms transform, transduce, and transfect are used interchangeably herein. In a preferred embodiment of this invention, the genetic material comprises transfected cells.

Transformed cells deliver products and therapeutic agents of interest at the transplant site. The delivery media is formulated as needed to maintain cell function and viability. Cells used in cell therapy are derived, for example, from the patient, or from a different source, including mammalian or non-mammalian sources, and from a variety of tissues and organs, including for example, bone marrow, blood, or liver among others. In general, cells are of human origin (autologous or allogenic) or of animal origin (xenogenic). This invention encompasses the use of cells in a wide range of developmental and growth conditions. For example, the use of differentiated cells, undifferentiated cells, stem cells, or progenitor cells, are all contemplated within the scope of this invention. Undifferentiated cells, if desired, are

chemically or physically induced to differentiate into a desired cell type.

The vector, according to the invention described herein, comprises a recombinant vector. Preferably, the vector is a viral or plasmid vector, more preferably the vector is a viral vector that is replication deficient, thermostable, site specific and delayed expression
5 viral vector. Most preferably, the viral vector is stable, withstands coating processes, and has low immunogenicity. An example of the preferred vector of this invention is the adenoassociated viral vector.

In a preferred embodiment of the invention, the vector of the present invention is a delayed expression vector that delays the expression of the first polynucleotide generally
10 from about 1 to about 3 weeks after administration to a patient. The expression of products and the stability of such expression within the body of a patient are ultimately influenced by factors, such as, the particular site of administration, i.e., organ, tissue or cell types, within a patient's body.

The carrier of this invention comprises, for example, a viral vector, non-viral vector,
15 non-plasmid vector or naked nucleic acid. The carrier is preferably an early expression carrier that provides transient expression of the second polynucleotide of interest which it carries. The early expression carrier generally results in expression of the second polynucleotide within about 1 to about 2 days or sooner after administration of the medical device within the body of a patient. This transient expression may continue for several
20 weeks in target cells.

According to one embodiment of the invention, the first polynucleotide is carried by a delayed expression vector and the second polynucleotide is carried by an early expression

vector. The first polynucleotide integrates into the genome of cells at or around the target site and establishes a delayed, and stable expression with a level sufficient to produce a therapeutically effective amount of one or more products in these cells. An example of a delayed expression is an expression delayed from about two days to about three weeks. The
5 sufficient frequency of expression is an expression that is induced in from about 5% to about 90% of cells exposed to the vector. On average from about 20% to about 80% of the cells exposed to the vector express the product encoded by the first polynucleotide.

A preferred non-plasmid vector of this invention includes, for example, liposomes, lipofectin, lipoplexes, polyplexes, dextrans, starburst dendrimer conjugates, polybenzene
10 dimethyl sulfoxide, protamine sulfate, antibody conjugates, polylysine conjugates, gramicidin S, artificial conjugates, viral envelopes, viral-like particles, nano or micro particles, polyvinyl pyrrolidone, SP1017, or a combination thereof.

It should be understood that the design of the vector and the carrier, as discussed above, may depend on factors, such as, the choice of the host cell to be transformed and/or
15 the type of the products desired to be expressed. Moreover, the vector copy number, the ability to control that copy number and the expression of any other products encoded by the first or the second polynucleotide of this invention, such as antibiotic markers, or antisense molecules should also be considered.

Non-limiting examples of viral vectors or vectors derived from viral sources include
20 adenoviral vectors, herpes simplex vectors, papilloma vectors, adenoassociated viral vectors, retroviral vectors, alpha virus vectors, lentivirus vectors, and the like. As described above, the viral vector of this invention is preferably replication defective and, thus, unable to

replicate autonomously in the target cell. In general, the genome of the replication defective viruses, which is used within the scope of the present invention, lacks at least the region necessary for the replication of the virus in the infected cell. These regions can either be eliminated (in whole or in part), rendered non-functional or substituted by other sequences, in particular by the sequence of the gene of interest. The replication defective virus may retain the sequences of its genome necessary for encapsidating the viral particles.

As described above, a preferred vector of this invention is a viral vector derived from an adenovirus or adenoassociated virus (AAV). Adenoassociated viruses are DNA viruses of relatively short size which integrate, in a stable and site-specific manner, into the genome of cells which they infect. These viruses are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation. Furthermore, they do not appear to be involved in human pathologies and demonstrate low immunogenicity.

Two general types of adenoassociated virus vectors are used. In the first type, the capsid gene is deleted and foreign DNA (about 2 kb) is inserted at the deletion site. This type of vector retains the replicase gene and can integrate at a specific site in the host genome. The second type of vector simply contains one or more AAV terminal repeats (plus a few additional bases) on both ends of the foreign DNA. In some cases such a vector can integrate and transform with >50% frequency, but the incidence of site specificity may be reduced.

Various serotypes of adenovirus having varying structures and properties exist. Of these serotypes, preference is given, within the scope of the present invention, to type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin, but other adenoassociated subtypes, such as, subtypes 1, 3, 4, and 6-42 may also be used. Those

adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, or murine sources. Preferably, the adenovirus of animal origin is a canine adenoassociated virus type 2 (CAV2) or it is of a mixed human and canine origin.

5 Included within the scope of the present invention is the use of adenoviruses sharing the major structural features of Ad:Pac-beta Galactosidase (beta-Gal) gene. That is, the invention includes the use of a replication deficient E1-, E3-deleted adenovirus comprising, for example, E1a enhancer/packaging signals at the 3' end. The viruses have in the E1 deletion site a non-adenoviral encoding sequence operably linked to a promoter. The non-adenoviral encoding sequence can be a marker gene (such as the nuclear localizing beta-Gal
10 gene, the luciferase gene, and the like). The encoding sequence can also be a gene encoding a therapeutically active molecule (examples of which are set forth above). The promoter to which the encoding sequence is operably linked is, for example, a strong viral promoter, such as the CMV promoter/enhancer or the respiratory syncytial virus (RSV) promoter, a
15 tissue specific promoter, or an inducible promoter (*i.e.*, the metallothionine promoter).

The vector and carrier carry the first and the second polynucleotide, respectively. The first and the second polynucleotide are the same or a different polynucleotides according to this invention and are in any molecularly acceptable form. Molecularly acceptable forms include, for example, DNA, ribozymes, anti-sense DNA or RNA, naked DNA, cDNA, RNA,
20 DNA/RNA hybrid, genomic DNA, and the like.

The first or second polynucleotide, or both encodes one or more products. Products comprise, for example, proteins, peptides, polypeptides, or polynucleotide molecules in sense

or antisense orientation. A product is understood to be any translational, post-translationally modified, or non-translational product of a polynucleotide regardless of size and form. Products, include as a primary example, those products that can compensate for a defect or deficiency in an animal, or those that act through toxic effects to limit or remove harmful
5 cells from the body.

The first therapeutic agent of this invention comprises genetic materials whereas the second therapeutic agent of the invention may comprise either genetic or non-genetic materials. The non-genetic material comprises any molecule or compound that induces a beneficial biological or medical reaction *in vitro*, *ex vivo*, or *in vivo*. An example of a
10 beneficial biological reaction is a reaction that stimulates and increases the chance of incorporation of the genetic material into the cells.

Included within the scope of the therapeutic agents of the invention are those agents that enhance gene transfer and integration into cells and tissues. These agents include compounds such as, for example, polybrene, poly-L-lysine, dextran sulfate, polyvinyl
15 pyrrolidone, SP1017 (Supratek Pharma), other polycationic substances, dexamethasone, substances which can increase the permeability of tissues such as detergents and lipids, for example, NP-40, and SDS that increase the permeability of tissues. Further examples of the therapeutic agents of the invention include immunosuppressants, such as, cyclosporin, dexamethasone, and antibodies against cytokines, such as, TNF-alpha, among others.

20 Non-limiting examples of products and therapeutic agents of the invention include: anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPACK (dextrophenylalanine proline arginine chloromethylketone); tissue plasminogen activator;

erythropoietin; antioxidants; angiogenic and anti-angiogenic agents and factors; agents blocking smooth muscle cell proliferation such as rapamycin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation; anti-inflammatory agents such as estrogen; calcium entry blockers; antineoplastic/antiproliferative/anti-mitotic agents such as , angiostatin and thymidine kinase inhibitors; nitrofurantoin; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; nitric oxide synthase (NOS); anti-coagulants such as D-Phe-Pro-Arg, an RGD peptide-containing compound; antithrombin compounds; platelet receptor antagonists; anti-thrombin antibodies; anti-platelet receptor antibodies; prostaglandin inhibitors; platelet inhibitors; vascular cell growth promoters; growth factor receptor antagonists; transcriptional activators and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors; growth factor receptor antagonists; transcriptional repressors; translational repressors; replication inhibitors; inhibitory antibodies; antibodies directed against growth factors; bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; agents which interfere with endogenous vasoactive mechanisms; and survival genes which protect against cell death, such as anti-apoptotic Bcl-2 family factors.

According to one embodiment of the invention, the first, or the second polynucleotide, or both encode angiogenic and anti-angiogenic agents such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, hif-1, epidermal growth factor, transforming growth factor α and β , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α , hepatocyte growth factor and insulin

like growth factor, AKT, cell cycle inhibitors including CDK inhibitors, retinoblastoma, p53, p16, p27, anti-restenosis agents, thymidine kinase ("TK"), FAS ligand, hKIS, heme oxygenase, nitric oxides, and combinations thereof.

Still other products, which can be encoded by the first or the second polynucleotide sequences, or both include monocyte chemoattractant protein ("MCP-1"), and the family of bone morphogenic proteins ("BMP's"). The known proteins include BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively or, in addition, molecules capable of inducing an upstream or downstream effect on BMP expression can be provided. Such molecules include any of the "hedgehog" proteins, or the nucleic acids encoding them.

In general, the first or the second polynucleotide, or both may each be operably linked to at least one transcriptional regulatory sequence in a manner that allows expression of the polynucleotide sequence. Regulatory sequences are art-recognized and are selected to direct gene expression. Accordingly, the term transcriptional regulatory sequence includes promoters, enhancers and other expression control elements. Such regulatory sequences are described in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990), incorporated herein by reference.

The regulatory sequences, within the scope of the invention can include, for example, sequences which are naturally responsible for expressing a gene, provided that these

sequences are also capable of functioning in the infected cell. The sequences can also be sequences of a different origin (responsible for expressing or regulating the expression of different proteins or even synthetic proteins). In particular, the sequences can be sequences of eukaryotic or viral genes or sequences derived therefrom, which sequences, for example, stimulate or repress transcription of a gene in a specific or non-specific manner or in an inducible or non-inducible manner. As an example, they can be promoter sequences derived from the host genome or from the genome of a virus, in particular the promoters of the adenoviral E1A and MLP genes, CMV or LTR-RSV promoter.

Other regulatory sequences within the scope of this invention include eukaryotic promoters comprising ubiquitous promoters (HPRT, vimentin, actin, tubulin, etc.); intermediate filament promoters (desmin, neurofilaments, keratin, GFAP, etc.); therapeutic gene promoters (MDR type, CFTR, factor VIII, etc.); tissue-specific promoters (actin promoter in smooth muscle cells); promoters which are preferentially activated in dividing cells, or promoters which respond to a stimulus (steroid hormone receptor, retinoic acid receptor, etc.). The early and late promoters of SV40; adenovirus or cytomegalovirus immediate early promoter; lac system; trp system; T7 promoter, whose expression is directed by T7 RNA polymerase; major operator and promoter regions of phage lambda; control regions for viral coat protein; promoter for 3-phosphoglycerate kinase or other glycolytic enzymes; promoters of acid phosphatase, *i.e.*, Pho5; promoters of the yeast alpha-mating factors; polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof, are included within the scope of this invention.

In a preferred embodiment of the invention, the first polynucleotide, the second polynucleotide, or both are linked, upstream of the coding sequence, to a signal sequence which directs the synthesized products into the secretory pathways of the target cell. While this signal sequence can be a natural signal sequence, it can also be any other functional signal sequence (that of the gene for thymidine kinase, for example), or an artificial signal sequence.

The amount of genetic material carried on the medical device is an effective expression-inducing amount. As used herein, the term "effective expression-inducing amount" means that amount of the genetic material that effectuates expression of a product encoded by one or more of the polynucleotide sequence(s) of interest. Means for determining an effective expression-inducing amount of a nucleic acid sequence is well known in the art.

As described above, the first and the second polynucleotide of this invention are carried by the vector and carrier, respectively. According to their particular structure and design, vector and carrier molecules affect expression and integration of the polynucleotides within the body of the recipient. The vector and carrier system of this invention ensure continued expression of a product *in vivo*.

According to another embodiment of the invention, the second polynucleotide is the same as the first polynucleotide, and is carried by an early expression vector that either integrates into the genome of the target cells or enters a transient expression route expressing the product(s) transiently in target cells. Transient expression usually lasts about one to about four weeks after administration of the medical device to a patient.

For example, the first therapeutic agent comprises a polynucleotide sequence encoding a cell cycle inhibitor gene, such as RB, or a promoter of endothelialization, such as vascular endothelial growth factor (VEGF). These genes are carried by a delayed expression vector. The second therapeutic agent comprises a polynucleotide sequence
5 encoding a cytotoxic gene such as FasL, which is carried by an early expression carrier. Therefore, the release kinetics and the duration of release of the first and the second therapeutic agents are controlled.

In general, the release kinetics of the genetic material are governed by several factors, including for example, the structure of the medical device, the structure, porosity, and
10 thickness of the polymeric coating; the nature of the genetic material (*i.e.*, transformed cells, polynucleotide carriers, etc.), the target site of therapy, and so on. A fine balance of these parameters provides a controlled, and stable release of the genetic material from the device coating into or proximal to a target site within the body of a patient.

Expressed products, according to the invention, are in general useful in any
15 application for treating, preventing, or otherwise affecting the course of a disease or tissue or organ dysfunction. For example, products are used to inhibit angiogenesis, prevent or treat restenosis, treat a cardiomyopathy, heart failure, or other dysfunction of the heart; treat cystic fibrosis or other dysfunction of the lung; treat or inhibit malignant or non-malignant cell proliferation; or to treat inducing nerve, blood vessel or tissue regeneration in a particular
20 tissue or organ.

A preferred embodiment of this invention is to provide treatment of vascular thrombosis and angioplasty restenosis, particularly coronary vascular thrombosis, and

angioplasty restenosis, thereby to decrease incidence of vessel rethrombosis and restenosis, unstable angina, myocardial infarction and sudden death. The medical device and method of this invention can be used to treat patients having severe complications resulting from thrombus. Specific examples include patients with acute myocardial infarction (AMI) and
5 patients that have failed PTCA (percutaneous transluminal coronary angioplasty) and have abrupt thrombotic closure of the targeted artery.

Organs and tissues that are treated by the methods of the present invention include any mammalian tissue or organ, whether injected or implanted and whether *in vivo* or *ex vivo*. Non-limiting examples include the heart, lung, brain, liver, skeletal muscle, smooth muscle,
10 kidney, bladder, intestines, stomach, pancreas, ovary, prostate, cartilage and bone. Other organ systems susceptible to treatment include any organ system in which material flows through the organ from a source, so that a factor can be administered in a coating. Exemplary organs include lymph nodes, the bile duct, the urinary tract, the lungs, the space occupied by the cerebro-spinal fluid, and the like. Examples of other tissues which can be treated in this
15 manner include the stomach and intestines, where growth factors help accelerate repair of ulceration, repair of external ulceration of skin, and general wound repair.

It will be appreciated that because transformation of appropriate target cells *in vivo* represents a first step in gene therapy, choice of the particular gene delivery system will depend on such factors as the phenotype of the intended target and the route of
20 administration. Furthermore, it will be recognized that the particular polynucleotide construct provided for *in vivo* transformation is also useful for *in vitro* transformation of cells, such as for use in the *ex vivo* or *in situ* tissue culture systems.

Having now fully described the invention, the same would be more readily understood by reference to specific examples which are provided by way of illustration, and not intended to be limiting of the invention, unless herein specified.

5 **Example 1. Intravascular Local Gene Transfer Mediated by Coated Metallic Stent**

 A replication-defective recombinant adenovirus carrying Lac Z reporter gene for nuclear-specific β -galactosidase (Ad- β gal) is used in this study. Coating of the stent is performed by immersing a metallic stent in gelatin solution containing crosslinker for 10 seconds, then air drying. The thickness of the coating is controlled to about 5-10 μ m. The coated stent is mounted on a 4.0 or 3.0 mm PTCA (percutaneous transluminal coronary angioplasty) balloon and submersed into Ad- β gal viral stock (2×10^{10} pfu/ml) for 3 min then implanted into carotid arteries in a rat. Coating of the stent and implantation is repeated in a significant number of rats.

 The animals are sacrificed at 7, 14 and 21 days after implantation. β -galactosidase expression is assessed by X-Gal staining. The expression of transgene can be detected in all animals. In vessels with denuded endothelium gene expression is found in sub-intima, media and adventitia. This study shows the feasibility and efficiency of adenovirus-mediated gene transfer to localized arterial wall by a protein-coated metallic stent.

**Example 2. Fabrication of Resorbable Microporous Intravascular Stents
or Gene And Cell Therapy Applications**

Resorbable, microporous endoluminal stents are prepared from poly-L-lactic
5 acid (PLLA)/poly ϵ -caprolactone (PCL) blends. Both helical and tube stent designs are
obtained by solvent casting and flotation-precipitation fabrication techniques. A range of
PLLA/PCL blend ratios and process variables are employed to investigate their influence on
mechanical properties, porosity, and degradation rate of the stent. Polymer blends with
higher PLLA proportions exhibit higher elastic moduli and ultimate tensile strength, lower
10 elongation, porosity, and degradation rates than polymer blends with higher PCL content.
Stents with suitable mechanical properties for deployment and support of the vessel wall are
obtained. Poly(ethylene oxide) is incorporated into these devices using an acid swelling
technique, opening the pore structure and improving the hydrophilic character, thereby
enabling the uptake of recombinant adenoviral vectors. The 50:50 PLLA/PCL blended stents
15 are impregnated with recombinant adenovirus (AdCM β Gal, encoding a nuclear localizing
variant of *Escherichia coli* β -galactosidase). Cultured CV-1 cells incubated with stents
impregnated with the recombinant virus express nuclear localized β -galactosidase activity,
confirming that absorbed virus is released from the matrix in an infectious form, with kinetics
suggesting that genetically enhanced endovascular devices of this design are feasible.

Example 3. Biological Activity of the Released DNA

The biological activity of adenovirus DNA, released from the surface of a coated medical device, is investigated by transfecting HEK 293 cells *in vitro*. The result
5 indicates that the released DNA is biologically active and has a high transfection efficiency.

Example 4. Preparation of Replication Deficient Adenovirus Vectors

Using standard recombinant DNA techniques, replication deficient adenoviral
10 virions are produced that express a gene encoding vascular endothelial growth factor (VEGF). Successful recombination of the plasmid and the adenoviral DNA results in the generation of a full adenoviral genome (minus, for example, an E1 or E3 deletions), with the polynucleotide sequence of VEGF cloned into the E1 and/or E3 deleted regions. The adenovirus can include one or more endonuclease cleavage sites, *i.e.*, restriction sites unique
15 to the adenovirus. Various sites can be used. Preferably, however, the sequence recognized by the endonuclease is at least 6 bases in length, more preferably, at least 8, downstream from the cleavage site(s). An endonuclease cleavage site can also be present at the E3-deletion site. The recombinant virions are replication deficient because they lack essential E1 adenoviral gene sequences. However, the HEK293 cell line is stably transfected with the E1
20 gene, thus supplying its essential function in trans. The replication deficient recombinant adenovirus is thus replication efficient in 293 cells, producing cell lysis and virion production. The virions that are produced do not produce lytic infections in other cell types,

but they can express VEGF.

Example 5. Preparation of Replication Deficient Adenoassociated Virus Vectors

5

The replication defective recombinant adenoassociated virus vector (AAV) is prepared by cotransfecting a plasmid containing a polynucleotide sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus). The AAV terminal repeats (plus a few more bases) are present on both ends of the foreign DNA. The AAV recombinants which are produced are then purified by standard techniques. The replication defective recombinant adenoassociated vectors are also made by deleting the capsid gene and substituting the foreign DNA (about 2 kb). The vectors integrate into the genome of the recipient cells and transform these cells with >50% frequency.

10

15

Example 6. Pre Clinical/ Clinical Applications of the Adenoassociated Virus Gene Therapy

20

Experiment 1. A nitric oxide synthase (NOS)-containing adenoassociated vector is used following coronary angioplasty to prevent restenosis. Administration is effected via a catheter (*i.e.*, a balloon-tipped catheter) or, for example, via a stent. The NOS-SMC (smooth muscle cell) containing adenoassociated virus is used to promote reendothelialization and reduce proliferation of the injured segment, and thereby prevent

25

restenosis.

Experiment 2. A nitric oxide synthase (NOS)-containing adenoassociated vector is used to treat atherosclerotic arteries. Endothelial dysfunction is an early event in atherosclerosis. Introduction of a NOS-containing adenovirus at a lesion site prevents progression to complex lesions, and promotes healing once developed. Administration is effected as described above (i.e. by catheter or by stent).

Experiment 3. A nitric oxide synthase (NOS)-containing adenoassociated vector is used in anti-cancer therapy. NOS is used to promote cell death. Accordingly, the NOS-adenoviruses vector is delivered to well vascularized tumors to effect the generation of cytotoxic levels of NOS. Administration can be effected by direct injection or implantation into the tumor tissue or, for example, by intravascular injection. The particular isoform used is mNOS.

Example 7. *Expression of Two Products Encoded by Two Polynucleotide Sequences of Interest Carried By Two Expression Vectors*

The replication defective recombinant adenoassociated virus vector (AAV) is prepared by cotransfecting a plasmid containing vascular endothelial growth factor (VEGF) flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus). The AAV terminal repeats (plus a few more bases) are present on both ends of the foreign DNA. The AAV recombinants which are produced are then purified by standard techniques. The replication defective recombinant

adenoassociated vectors are also made by deleting the capsid gene and substituting the foreign DNA (about 2 kb) with a polynucleotide sequence encoding the whole or a portion of a cell cycle inhibitor gene or a promoter of endothelialization, such as vascular endothelial growth factor (VEGF) is cloned into the replication-defective AAV vector produced above.

- 5 The AAV recombinant vector thus produced is used as the delayed expression vector. The second sequence of interest is a polynucleotide sequence encoding FAS ligand. This sequence is cloned into an adenovirus derived vector under the direction of the early promoter of SV40. Both the AAV recombinant vector and the adenovirus derived vector are applied onto, or impregnated into, one or several layers of a coating on the surface of a stent.
- 10 The stent is administered to a patient following coronary angioplasty to prevent restenosis. The VEGF containing AAV recombinant vector is used to promote reendothelialization of the injured segment, and thereby prevent restenosis.

- Both the early expression vector and the delayed expression vectors are effective in this therapy. The delayed expression vector integrates into the genome of the recipient cells and transform these cells with >50% frequency. The early expression vector transiently expresses the product of FAS L after about 1 or 2 days of delivery to target cells. The transient expression of FAS L continues about 1 to 4 weeks in the patient's body.
- 15

What Is Claimed Is:

Claim 1. A medical device comprising:

5 a biocompatible structure carrying a genetic material, said biocompatible structure comprising a polymeric coating that coats at least a portion of said structure, said genetic material comprising:

(a) a first therapeutic agent comprising a vector containing a first polynucleotide that establishes a gene expression sufficient to produce a therapeutically sufficient amount of one or more products encoded by said first polynucleotide; and

10 (b) a second therapeutic agent comprising at least one of (i) a second polynucleotide carried by a carrier; (ii) a protein; (iii) a non-genetic therapeutic agent, or (iv) cells.

Claim 2. The medical device of claim 1, wherein said second therapeutic agent is said second polynucleotide, said vector establishes a delayed gene expression, and said carrier establishes an early gene expression.

Claim 3. The medical device of claim 1, wherein said vector is an adenoassociated virus vector.

Claim 4. The medical device of claim 1, wherein said carrier is a viral vector, plasmid vector, non-plasmid vector, or a combination thereof.

20 Claim 5. The medical device of claim 1, wherein said carrier comprises a naked nucleic acid molecule.

Claim 6. The medical device of claim 4, wherein said non-plasmid vector comprises

liposomes, lipofectin, lipoplexes, polyplexes, dextrans, starburst, dendrimer conjugates, polybenrene dimethyl sulfoxide, protamine sulfate, antibody conjugates, polylysine conjugates, gramacidin S, artificial conjugates, viral envelopes, viral-like particles, nano or micro particles, or a combination thereof.

5 Claim 7. The medical device of claim 1, wherein said first polynucleotide and said second polynucleotide are the same.

 Claim 8. The medical device of claim 1, wherein said vector, said carrier, or both are site specific.

 Claim 9. The medical device of claim 1, wherein said first polynucleotide, said
10 second polynucleotide, or both encodes one or more products selected from the group consisting of: nitric oxide synthase; human fibroblast growth factor; vascular endothelial growth factor; tissue plasminogen activator; anti-thrombogenic agents; erythropoietin; antioxidants; angiogenic and anti-angiogenic agents; agents blocking smooth muscle cell proliferation; angiopeptin; monoclonal antibodies capable of blocking smooth muscle cell
15 proliferation; anti-inflammatory agents; calcium entry blockers; antineoplastic/antiproliferative/ anti-mitotic agents; anti-coagulants; antithrombin compounds; platelet receptor antagonists; anti-thrombin antibodies; anti-platelet receptor antibodies; prostaglandin inhibitors; platelet inhibitors; vascular cell growth promoters; transcriptional activators; translational promoters; vascular cell growth inhibitors; growth
20 factor receptor antagonists; transcriptional repressors; translational repressors; or replication inhibitors.

 Claim 10. The medical device of claim 1, wherein said vector comprises a viral

vector.

Claim 11. The medical device of claim 10, wherein said vector is thermostable, replication-deficient, non-immunogenic, or a combination thereof.

Claim 12. The medical device of claim 1 wherein said expression is achieved in
5 about 20% to about 80% of cells exposed to said genetic material.

Claim 13. The medical device of claim 2, wherein said delayed expression is an expression delayed from about two days to about three weeks after administration *in vivo*.

Claim 14. The medical device of claim 1, wherein said vector, said carrier, or both contain regulatory sequences.

10 Claim 15. The medical device of claim 1, wherein said cells comprise transfected, transformed or transduced cells.

Claim 16. The medical device of claim 15, wherein said cells are autologous cells.

Claim 17. The medical device of claim 1, wherein said biocompatible coating comprises polyurethane, silicone, EVA, poly-L-lactic acid /poly ε-caprolactone blends, or a
15 combination thereof.

Claim 18. The medical device of claim 1, wherein said polymer coating is from about 1 to about 40 layers having a thickness of from about 1 to about 10 μm/ layer of coating.

Claim 19. The medical device of claim 1, wherein said structure is a stent.

Claim 20. The medical device of claim 19, wherein said stent is a metallic stent.

20 Claim 21. The medical device of claim 19, wherein said stent is a coil spring made from aliphatic polyester blends.

Claim 22. The medical device of claim 19, wherein said stent is a microporous tube

made from aliphatic polyester blends.

Claim 23. The medical device of claim 1, wherein said first therapeutic agent and said second therapeutic agent are applied onto or impregnated into a same layer of said polymer coating.

5 Claim 24. A method of inhibiting or treating restenosis in a patient, said method comprising administering at a predetermined site within the body of said patient the device of claim 1.

Claim 25. The method of claim 23, wherein said site is a site of mechanical injury to an arterial wall produced by treatment of an atherosclerotic lesion by angioplasty.

10 Claim 26. A method of controlled delivery of a genetic material to a mammalian body comprising;

(A) applying a polymer coating to at least a portion of a medical device;

(B) applying a genetic material to said polymer coating to obtain a genetically coated medical device, said genetic material comprising: (a) a first therapeutic agent
15 comprising a vector containing a first polynucleotide that establishes a gene expression sufficient to produce a therapeutically sufficient amount of one or more products encoded by said first polynucleotide; and (b) a second therapeutic agent comprising at least one of (i) a second polynucleotide carried by a carrier; (ii) a protein; (iii) a non-genetic therapeutic agent; or (iv) cells; and

20 (C) inserting or implanting said genetically coated medical device at a predetermined site in said mammal.

Claim 27. The method of claim 26, wherein said vector is adenoassociated virus

vector.

Claim 28. The method of claim 26, wherein said carrier is a viral vector, plasmid vector, a non-plasmid vector, or a combination thereof.

5 Claim 29. The method of claim 26, wherein said carrier comprises a naked nucleic acid molecule.

Claim 30. The method of claim 26, wherein said non-plasmid vector comprises liposomes, lipofectin, lipoplexes, polyplexes, dextrans, starburst, dendrimer conjugates, polybenrene dimethyl sulfoxide, protamine sulfate, antibody conjugates, polylysine conjugates, gramacidin S, artificial conjugates, viral envelopes, viral-like particles, nano or
10 micro particles, or a combination thereof.

Claim 31. The method of claim 26, wherein said first polynucleotide and said second polynucleotide are the same.

Claim 32. The method of claim 26, wherein said vector, said carrier, or both are site specific.

15 Claim 33. The method of claim 26, wherein said first therapeutic agent, said second therapeutic agent, or both cause the production of one or more products selected from the group consisting of: nitric oxide synthase; human fibroblast growth factor; vascular endothelial growth factor; tissue plasminogen activator; anti-thrombogenic agents; erythropoietin; antioxidants; angiogenic and anti-angiogenic agents; agents blocking smooth
20 muscle cell proliferation; angiopeptin; monoclonal antibodies capable of blocking smooth muscle cell proliferation; anti-inflammatory agents; calcium entry blockers; antineoplastic/antiproliferative/ anti-mitotic agents; anti-coagulants; antithrombin

compounds; platelet receptor antagonists; anti-thrombin antibodies; anti-platelet receptor antibodies; prostaglandin inhibitors; platelet inhibitors; vascular cell growth promoters; transcriptional activators; translational promoters; vascular cell growth inhibitors; growth factor receptor antagonists; transcriptional repressors; translational repressors; replication inhibitors, or a combination thereof.

Claim 34. The method of claim 26, wherein said vector comprises a viral vector.

Claim 35. The method of claim 34, wherein said viral vector is thermostable, replication-deficient, non-immunogenic, or a combination thereof.

Claim 36. The method of claim 26, wherein said expression is achieved in about 20% to about 80% of cells exposed to said genetic material.

Claim 37. The method of claim 26, wherein said vector is a delayed expression vector and said carrier is an early expression carrier.

Claim 38. The method of claim 37, wherein said delayed expression is an expression delayed from about two days to about 3 weeks after administration in vivo.

Claim 39. The method of claim 26, wherein said vector, said carrier, or both contain regulatory sequences.

Claim 40. The method of claim 26, wherein said cells comprise transfected, transformed or transduced cells.

Claim 41. The method of claim 40, wherein said cells are autologous cells.

Claim 42. The method of claim 26, wherein said coating comprises polyurethane, silicone, EVA, poly-L-lactic acid /poly ϵ -caprolactone blends, or a combination thereof.

Claim 43. The method of claim 26, wherein said polymer coating is from about 1 to

Docket No. 2844/56301

about 40 layers having a thickness of from about 1 to about 10 μm / layer of coating.

Claim 44. The method of claim 26, wherein said structure is a stent.

Claim 45. The method of claim 44, wherein said stent is a coil spring made from aliphatic polyester blends.

5 Claim 46. The method of claim 44, wherein said stent is a microporous tube made from aliphatic polyester blends.

Claim 47. The method of claim 44, wherein said stent is a metallic stent.

Claim 48. The method of claim 26, wherein said first therapeutic agent and said second therapeutic agent are applied onto or impregnated into a same layer of said polymer
10 coating.

Claim 49. The method of claim 26, wherein said therapeutic agent is a protein.

Claim 50. The method of claim 26, wherein said therapeutic agent is a small molecule.

Claim 51. The method of claim 26, wherein said therapeutic agent is a non-protein
15 based agent.

ABSTRACT

5 An implantable or insertable medical device suitable for gene or cell therapy regimens, and method of making and using same are disclosed. The medical device contains a biocompatible structure carrying a genetic material. The biocompatible structure includes a polymeric coating that coats at least a portion of the structure. The genetic material includes a first therapeutic agent comprising a vector containing a first polynucleotide
10 sequence that establishes a gene expression sufficient to produce a therapeutically sufficient amount of one or more products encoded by said first polynucleotide; and a second therapeutic agent comprising at least one of (i) a second polynucleotide carried by a carrier; (ii) a protein; (iii) a non-genetic therapeutic agent, or (iv) cells.

 The medical device and method of this invention facilitate successful integration as
15 and a long term expression of one or more genetic-based and non-genetic based products within a patient's body.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

**INSERTABLE OR IMPLANTABLE MEDICAL DEVICES SUITABLE
FOR GENE THERAPY REGIMENS**

the specification of which is filed herewith.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by an amendment, if any, specifically referred to in this declaration.

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.


I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

None

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application:

None

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor : Maria Palasis
Inventor's signature : 
Date : 3/23/00
Residence : 65 Martin Road
Wellesley, MA 02181
Citizenship : U.S.A.
Post Office Address: : Same as above

DC307017v1


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
INFORMATION DISCLOSURE STATEMENT		Docket Number: 12013/56302	
Serial No. To be assigned	Filing Date Herewith	Examiner To Be Assigned	Art Unit To Be Assigned
Invention Title INSERTABLE OR IMPLANTABLE MEDICAL DEVICES SUITABLE FOR GENE THERAPY REGIMES		Inventors Maria PALASIS	

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the following documents to the attention of the Examiner. These documents are listed on the attached list of references. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "Documents Cited" on any patent to issue therefrom
2. The filing of this Information Disclosure Statement and the enclosed list of references, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. Copies of each of the cited documents listed are not required and therefore not enclosed. Copies of each of the documents were previously provided to the Examiner by Applicant or cited by the Examiner during prosecution of the prior application to which the accompanying application claims priority, namely, U.S. Patent Application Serial No. 09/542,935 filed October 15, 2001.

Dated: SEPT. 14, 2007

By:


Joseph A. Coppola Reg. No. 38,413

KENYON & KENYON LLP
One Broadway
New York, N.Y. 10004
Customer No. 26646

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number	09/542,935
Filing Date	April 4, 2000
First Named Inventor	Maria PALASIS
Group Art Unit	1635
Examiner Name	Brian A. Whiteman
Attorney Docket Number	12013/56301

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 20020098278	07-25-2002	Brian Bates, et al	
		US- 20020051730	05-02-2002	Stanko Bodnar, et al	
		Re. 32,307	12-16-86	Werner Glatt, et al.	
		US- 4,529,614	07/16/1985	James Burnes	
		US- 4,535,006	08/13/1985	Dietmar Naunapper, et al.	
		US- 4,740,207	04-26-1998	Jeffrey Kreamer	
		US- 4,753,652	06-28-1988	Robert Langer, et al	
		US- 4,758,151	07-19-1988	Pietro Arru, et al	
		US- 4,768,507	09-06-1988	Robert Fischell, et al	
		US- 4,776,337	10-11-1988	Julio Palmaz	
		US- 4,795,458	01-03-1989	Barrie Regan	
		US- 4,888,009	12-19-1989	David Lederman, et al	
		US- 5,007,926	04-16-1991	Garrett Derbyshire	
		US- 5,018,090	05-28-1991	Leonard Pinchuk	
		US- 5,041,100	08-20-1991	Stephen Rowland, et al	
		US- 5,053,048	10-01-1991	Leonard Pinchuk	
		US- 5,092,877	03-03-1992	Leonard Pinchuk	
		US- 5,102,417	04-07-1992	Julio Palmaz	
		US- 5,171,217	12-15-1992	Keith March, et al	
		US- 5,171,812	12-15-1992	Abraham Domb	
		US- 5,175,235	12-29-1992	Abraham Domb, et al	
		US- 5,192,307	03-09-1993	W. Henry Wall	
		US- 5,221,698	06-22-1993	Gordon Amidon, et al	
		US- 5,226,913	07-13-1993	Leonard Pinchuk	
		US- 5,234,456	08-10-1993	Thomas Silvestrini	
		US- 5,236,503	08-17-1993	David Jones	
		US- 5,240,963	08-31-1993	Abraham Domb, et al	
		US- 5,272,012	12-21-1993	Margaret Opolski	
		US- 5,282,823	02-01-1994	Robert Schwartz, et al	
		US- 5,304,121	04-19-1994	Ronald Sahatjian	
		US- 5,334,201	08-02-1994	Kevin Cowan	
		US- 5,342,348	08-30-1994	Aaron Kaplan	
		US- 5,342,621	08-30-1994	Robert Eury	
		US- 5,345,933	09-13-1994	Lars-Olof Peterson, et al	
		US- 5,380,299	01-10-1995	Neal Fearnot, et al	
		US- 5,383,928	01-24-1995	Neal Scott, et al	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	09/542,935
Filing Date	April 4, 2000
First Named Inventor	Maria PALASIS
Group Art Unit	1635
Examiner Name	Brian A. Whiteman
Attorney Docket Number	12013/56301

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 5,419,760	05-30-1995	Hugh Narcisco, Jr	
		US- 5,423,885	06-13-1995	Michael Williams	
		US- 5,429,634	07-04-1995	Hugh Narcisco	
		US- 5,437,889	08-01-1995	David Jones	
		US- 5,439,686	08-08-1995	Neil Desai, et al	
		US- 5,443,458	08-22-1995	Robert Eury	
		US- 5,443,496	08-22-1995	Robert Schwartz, et al	
		US- 5,447,724	09-05-1995	Michael Helmus, et al	
		US- 5,457,113	10-10-1995	George Cullinan, et al	
		US- 5,462,937	10-31-1995	George Cullinan, et al	
		US- 5,464,450	11-07-1995	Paul Buscemi, et al	
		US- 5,464,650	11-07-1995	Eric Berg, et al	
		US- 5,475,052	12-12-1995	Woonza Rhee, et al	
		US- 5,486,191	01-23-1996	Pankaj Pasricha, et al	
		US- 5,500,013	03-19-1996	Paul Buscemi, et al	
		US- 5,512,055	04-30-1996	Abraham Domb, et al	
		US- 5,516,781	05-14-1996	Randall Morris, et al	
		US- 5,527,337	06-18-1996	Richard Stack, et al	
		US- 5,545,208	08-13-1996	Rodney Wolff, et al	
		US- 5,545,213	08-13-1996	James Keogh, et al	
		US- 5,551,954	09-03-1996	Paul Buscemi, et al	
		US- 5,554,182	09-10-1996	Thomas Dinh, et al	
		US- 5,562,922	10-08-1996	Thomas Lambert	
		US- 5,571,166	11-05-1996	Thomas Dinh, et al	
		US- 5,575,815	11-19-1996	Marvin Slepian, et al	
		US- 5,578,075	11-26-1996	Michael Dayton	
		US- 5,588,962	12-31-1996	Peter Nicholas, et al	
		US- 5,591,227	01-07-1997	Thomas Dinh, et al	
		US- 5,599,352	02-04-1997	Thomas Dinh, et al	
		US- 5,603,694	02-18-1997	Joe Brown, et al	
		US- 5,605,696	02-25-1997	Robert Eury, et al	
		US- 5,607,417	03-04-1997	Christopher Balich, et al	
		US- 5,607,475	03-04-1997	Linda Cahalan, et al	
		US- 5,609,629	03-11-1997	Neal Fearnot, et al	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of

6

Complete if Known

Application Number	09/542,935
Filing Date	April 4, 2000
First Named Inventor	Maria PALASIS
Group Art Unit	1635
Examiner Name	Brian A. Whiteman
Attorney Docket Number	12013/56301

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 5,624,411	04-29-1997	Ronald Tuch	
		US - 5,628,785	05/13/1997	Schwartz, et al.	
		US- 5,653,760	08/05/1997	Bruce Saffran	
		US- 5,679,400	10-21-1997	Ronald Tuch	
		US -5,698,531	12/16/1997	Nabel, et. al.	
		US- 5,776,184	07-07-1998	Ronald Tuch	
		US- 5,824,048	10-20-1998	Ronald Tuch	
		US- 5,824,049	10-20-1998	Anthony Ragheb, et al	
		US- 5,833,651	11-10-1998	Maura Donovan, et al	
		US- 5,837,008	11-17-1998	Eric Berg, et al	
		US- 5,843,172	12-01-1998	John Yan	
		US- 5,851,217	12-22-1998	Rodney Wolff, et al	
		US- 5,851,231	12-22-1998	Rodney Wolff, et al	
		US- 5,871,535	02-16-1999	Rodney Wolff, et al	
		US- 5,873,904	02-23-1999	Anthony Ragheb, et al	
		US- 5,879,697	03-09-1999	Ni Ding, et al	
		US- 5,900,246	05-04-1999	Thomas Lambert	
		US- 5,981,568	11-09-1999	Lawrence Künz, et al	
		US- 5,997,468	12-07-1999	Rodney Wolff, et al	
		US- 6,096,070	08-01-2000	Anthony Ragheb, et al	
		US- 6,099,561	08-08-2000	Eckhard Alt	
		US- 6,099,562	08-08-2000	Ni Ding, et al	
		US- 6,120,536	09-19-2000	Ni Ding, et al	
		US- 6,120,847	09-19-2000	Dachuan Yang, et al	
		US- 6,146,358	11-14-2000	Stanton Rowe	
		US- 6,153,252	11-28-2000	Syed Hossainy, et al	
		US- 6,187,370	02-13-2001	Thomas Dinh, et al	
		US- 6,206,915	03-27-2001	John Fagan, et al	
		US- 6,206,916	03-27-2001	Joseph Furst	
		US- 6,228,845	05-08-2001	Maura Donovan, et al	
		US- 6,273,913	08-14-2001	Stuart Kamille	
		US- 6,299,604	10-09-2001	Anthony Ragheb, et al	
		US- 6,355,055	03-12-2002	Ron Waksman, et al	
		US- 6,379,382	04-30-2002	Jun Yang	
		US- 6,379,691	04-30-2002	Eugene Tedeschi, et al	
		US- 6,395,326	05-28-2002	Daniel Castro, et al	
		US- 6,406,754	06-18-2002	Ralph Chappa, et al	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. (445459v1)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	09/542,935
Filing Date	April 4, 2000
First Named Inventor	Maria PALASIS
Group Art Unit	1635
Examiner Name	Brian A. Whiteman
Attorney Docket Number	12013/56301

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ⁴ - Kind Code ⁵ (if known)				
		EP 470246 B1	09-05-1991	Rodney Wolff, et al		
		EP 627226 B1	12-16-1998	Kevin Cowan		
		EP 747069 A2	12-11-1996	Neal Fearnot, et al		
		WO 00/45744	08-10-2000	Dachuan Yang, et al		
		WO 01/91918	12-06-2001	Steven Wu, et al		
		WO 9013332	12-15-1992	Abraham Domb		
		WO 9112779	09-05-1991	Rodney Wolff, et al		
		WO 9215286	09-17-1992	Abraham Domb, et al		
		WO 95/07691	03/23/1995	John D. Folts, et al.		
		WO 95/24929	09/21/1995	Edith Mathiowitz, et al.		
		WO 99/00071	01/07/1999	Elizabeth G. Nabel, et al.		
		WO 00/32255	06/08/2000	Kalpna R. Kamath, et al.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 6

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Maria PALASIS
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	12013/56302

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		5,833,651	11-1998	Donovan et al.	
		5,851,521	12-1998	Branellec et al.	
		5,869,037	2-1999	Crystal et al.	
		6,280,411	8-2001	Lennox	
		6,369,039	4-2002	Palasis et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Edelman E., et al., <i>Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury</i> , Proc. Natl. Acad. Sci. U.S.A., 87:3773-3777 (1990)	
		Okada T., et al., <i>Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation</i> , Neurosurgery, 25:892-898 (1989)	
		Avital B., et al., <i>Iontophoretic Transmyocardial Drug Delivery</i> , CIRC, 85:1582-1593 (1992)	
		Wilensky R., et al., <i>Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplasty</i> , Amer. Heart J., 122:1136-1140 (1991)	
		Okada T., et al., <i>Local Anticoagulation Without Systemic Effect Using a Polymer Heparin Delivery System</i> , Stroke, 19:1470-1476 (1988)	
		Dixit et al., J. Biol. Chem., 1990: 265:2973-8.	
		Lee et al., J. Biol. Chem., 1998; 273:288805-12.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NY01 1401892v1